Relatlimab was the first anti-LAG-3 mAb that entered clinical testing, as a mono- or combination therapy with nivolumab, in melanoma, renal cell carcinoma and non-small cell lung carcinoma (NSCLC) (NCT019680109), and it showed to restored T-cell functionality [48]. This evidence concerns the gene LAG3 and non-small cell lung carcinoma.